Physician profile
Mark Agulnik
NPI 1164448734
$303,006.39
in general payments reported to CMS, 2019-2025
31 companies · $30K in 2025
The $30K reported for 2025 was more than what 92% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86K · 2020: $29K · 2021: $39K · 2022: $40K · 2023: $11K · 2024: $68K · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $46K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $41K · Travel and Lodging: $13K · Food and Beverage: $5,425 · Honoraria: $3,570 · Gift: $212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $45,700.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $41,353.35 |
| Travel and Lodging | $12,672.29 |
| Food and Beverage | $5,425.17 |
| Honoraria | $3,570.00 |
| Gift | $211.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $86,254.54 | 2019-2025 | |
| Deciphera Pharmaceuticals INC. | $85,397.86 | 2020-2025 | Qinlock, Vimseltinib, Romvimza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27,072.72 | 2022-2024 | |
| Regeneron Healthcare Solutions, INC. | $25,692.47 | 2019-2024 | Libtayo |
| Daiichi Sankyo INC. | $17,491.61 | 2019-2025 | Turalio, Turalio, Enhertu |
| Springworks Therapeutics, INC. | $14,696.49 | 2024-2025 | Ogsiveo, Gomekli |
| E.R. Squibb & Sons, L.L.C. | $11,872.19 | 2019 | |
| Aadi Bioscience, INC. | $11,466.33 | 2022-2025 | Fyarro |
| Genzyme Corporation | $10,547.43 | 2019-2025 | |
| Blueprint Medicines Corporation | $5,740.00 | 2020-2021 | |
| Astrazeneca Pharmaceuticals Lp | $3,470.68 | 2019-2024 | Calquence |
| Eli Lilly and Company | $1,050.00 | 2021 | |
| Lantheus Medical Imaging, INC. | $800.00 | 2024 | |
| Foundation Medicine, INC. | $700.00 | 2019-2020 | |
| Galvanize Therapeutics, INC | $198.47 | 2023 | Aliya System |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $136.76 | 2024-2025 | Xt Cdx |
| Exelixis INC. | $134.79 | 2019 | |
| Janssen Biotech, INC. | $83.00 | 2019-2025 | Darzalex, Tecvayli |
| Sobi, INC | $61.69 | 2025 | |
| Beone Medicines USA, INC. | $41.01 | 2025 | Brukinsa |
| Astellas Pharma US INC | $28.84 | 2025 | Xospata |
| Merck Sharp & Dohme LLC | $25.86 | 2025 | Keytruda |
| Epizyme, INC. | $25.45 | 2022 | |
| Tactile Systems Technology INC | $18.20 | 2022 |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Agulnik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.